Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Roche Holding stock price, quote, forecast and news

ROG.SW
CH0012032048
855167

Price

277.50 CHF
Today +/-
+0 CHF
Today %
+0 %
P

Roche Holding Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Roche Holding, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Roche Holding from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Roche Holding’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Roche Holding. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Roche Holding’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Roche Holding’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Roche Holding’s growth potential.

Roche Holding Revenue, EBIT and net profit per share

DateRoche Holding RevenueRoche Holding EBITRoche Holding Net Income
2029e79.16 B CHF0 CHF17.51 B CHF
2028e72.8 B CHF25.51 B CHF16.07 B CHF
2027e69.3 B CHF24.17 B CHF15.31 B CHF
2026e67.86 B CHF22.87 B CHF14.75 B CHF
2025e65 B CHF21.52 B CHF13.75 B CHF
2024e61.44 B CHF19.82 B CHF12.54 B CHF
202358.72 B CHF18.53 B CHF11.5 B CHF
202263.28 B CHF19.92 B CHF12.42 B CHF
202162.8 B CHF18.53 B CHF13.93 B CHF
202058.32 B CHF18.97 B CHF14.3 B CHF
201961.47 B CHF20.23 B CHF13.5 B CHF
201856.85 B CHF18.71 B CHF10.5 B CHF
201753.3 B CHF16.92 B CHF8.63 B CHF
201650.58 B CHF16.93 B CHF9.58 B CHF
201548.15 B CHF16.06 B CHF8.86 B CHF
201447.46 B CHF16.98 B CHF9.33 B CHF
201346.78 B CHF17.39 B CHF11.16 B CHF
201245.5 B CHF16.66 B CHF9.43 B CHF
201142.53 B CHF14.61 B CHF9.34 B CHF
201047.47 B CHF13.49 B CHF8.67 B CHF
200949.05 B CHF12.28 B CHF7.78 B CHF
200845.62 B CHF13.9 B CHF8.97 B CHF
200746.13 B CHF14.47 B CHF9.76 B CHF
200642.04 B CHF11.73 B CHF7.88 B CHF
200535.51 B CHF8.78 B CHF5.92 B CHF
200429.52 B CHF6.19 B CHF6.61 B CHF

Roche Holding Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B CHF)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B CHF)EBIT (B CHF)EBIT MARGIN (%)NET INCOME (B CHF)NET INCOME GROWTH (%)DIV. (CHF)DIV. GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
14.7215.9718.7724.6627.5728.6729.1629.4531.2229.5235.5142.0446.1345.6249.0547.4742.5345.546.7847.4648.1550.5853.356.8561.4758.3262.863.2858.7261.446567.8669.372.879.16
-8.4517.5431.4111.784.011.710.996.00-5.4420.2918.399.73-1.127.53-3.22-10.416.982.821.461.445.055.386.658.13-5.117.680.76-7.214.635.804.402.115.068.72
69.0969.3867.5467.9667.8168.0471.4171.3773.3773.8673.9068.4070.2170.0570.2072.0072.5873.7873.6372.7970.7770.6970.5471.0771.7372.7469.1970.5673.39------
10.1711.0812.6816.7618.6919.5120.8221.0222.9121.826.2428.7632.3931.9634.4434.1830.8733.5734.4534.5534.0735.7537.640.444.0942.4243.4544.6543.09000000
3.23.463.764.374.734.334.84.955.776.198.7811.7314.4713.912.2813.4914.6116.6617.3916.9816.0616.9316.9218.7120.2318.9718.5319.9218.5319.8221.5222.8724.1725.510
21.7121.7020.0417.7217.1615.1016.4716.8018.4820.9824.7227.9031.3630.4625.0328.4134.3636.6237.1735.7833.3633.4731.7432.9232.9032.5229.5131.4731.5632.2633.1033.7034.8735.04-
3.373.9-2.034.395.768.653.7-4.033.076.615.927.889.768.977.788.679.349.4311.169.338.869.588.6310.513.514.313.9312.4211.512.5413.7514.7515.3116.0717.51
-15.63-152.09-316.2531.2450.02-57.25-208.90-176.23115.25-10.3433.0423.87-8.11-13.2111.337.810.9018.43-16.41-5.038.04-9.8521.6328.545.91-2.55-10.83-7.439.099.597.283.794.988.98
-----------------------------------
-----------------------------------
863863863863862.6855.2855839859849860862862861859857851855863863862860860860864865860808804000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Roche Holding Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Roche Holding is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M CHF)RECEIVABLES (M CHF)OTHER REC. (M CHF)INVENTORIES (M CHF)OTHER CURRENT LIAB. (M CHF)CURRENT ASSETS (M CHF)TANGIBLE ASSETS (M CHF)LONG-T. INVEST. (M CHF)LONG-T. REC. (M CHF)INTANGIBLE ASSETS (M CHF)GOODWILL (M CHF)OTHER NON-CURRENT ASSETS (M CHF)NON-CURRENT ASSETS (M CHF)TOTAL ASSETS (M CHF)LIABILITIESCOMMON STOCK (M CHF)ADDITIONAL PAID-IN CAPITAL (M CHF)RETAINED EARNINGS (M CHF)OTHER EQUITY (M CHF)UNREAL. GAINS/LOSSES (M CHF)EQUITY (M CHF)LIABILITIES (M CHF)PROVISIONS (M CHF)OTHER SHORT-TERM LIAB. (M CHF)SHORT-TERM DEBTS (M CHF)LONG-TERM DEBT PORTION (M CHF)SHORT-TERM REC. (M CHF)LONG-T. LIAB. (M CHF)DEFERRED TAXES (M CHF)OTHER LIAB. (M CHF)LONG-T. LIABILITIES (M CHF)DEBT (M CHF)TOTAL CAPITAL (M CHF)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Roche Holding provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Roche Holding's financial health and stability.

Assets

Roche Holding's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Roche Holding must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Roche Holding after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Roche Holding's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B CHF)DEPRECIATION (B CHF)DEFERRED TAXES (M CHF)CHANGES IN WORKING CAPITAL (M CHF)NON-CASH ITEM (B CHF)PAID INTEREST (B CHF)PAID TAXES (B CHF)NET CASH FLOW FROM OPERATING ACTIVITIES (B CHF)CAPITAL EXPENDITURES (M CHF)CASH FLOW FROM INVESTING ACTIVITIES (B CHF)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B CHF)INTEREST INCOME AND EXPENSES (M CHF)NET DEBT CHANGE (B CHF)NET CHANGE IN EQUITY (M CHF)CASH FLOW FROM FINANCING ACTIVITIES (B CHF)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M CHF)TOTAL DIVIDENDS PAID (M CHF)NET CHANGE IN CASH FLOW (B CHF)FREE CASH FLOW (M CHF)SHARE-BASED COMPENSATION (M CHF)
19951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
3.373.9-2.034.375.768.653.7-4.033.077.066.879.1711.4410.848.518.899.549.6611.379.549.069.738.8310.8714.1115.0714.9413.5312.36
1.121.211.492.072.452.852.992.982.812.812.312.442.542.652.692.552.372.422.382.623.643.943.893.594.294.564.443.843.46
1579000000000000000000000000000
-967-820-1,530-1,010-3,659-2,386-1,785-2,363-1,739-1,466-1,944-5,194-5,704-5,096-1,960-4,790-4,704-5,117-5,030-4,630-5,470-6,403-4,642-4,780-4,898-7,287-6,120-8,227-6,522
-1.01-1.245.56-1.82-2.83-5.190.194.393.11-1.082.743.913.463.787.87.695.758.047.058.48.037.739.9510.318.886.237.728.666.8
0.80.930.530.80.690.90.920.690.490.490.190.340.30.220.751.931.551.511.30.980.970.850.650.590.620.420.410.560.77
0.680.680.580.670.832.291.21.360.771.4922.84.493.511.772.792.593.333.342.983.73.743.913.293.543.243.344.13.62
2.533.133.493.621.733.925.090.987.257.349.9810.3311.7312.1817.0514.3412.9515.0115.7715.9315.251518.0219.9822.3918.5720.9817.816.1
-1,560-1,965-2,105-2,281-2,413-2,402-2,140-2,139-2,493-2,535-3,668-4,154-4,465-3,557-3,219-3,010-2,205-2,406-2,854-3,334-4,110-5,145-4,213-6,746-4,896-7,858-4,652-4,797-10,869
-0.2-0.86-3.16-7.92-0.87-0.83-3.73.541.56-2.02-5.69-7.45-5.79-1.72-3.083.53-0.35-4.51-1.3-12-4.28-4.51-6.46-7.2-8.63-9.07-6.55-2.92-10.64
1.361.11-1.06-5.641.551.57-1.565.684.060.52-2.02-3.3-1.321.840.146.541.85-2.111.55-8.67-0.170.63-2.25-0.45-3.74-1.21-1.91.870.23
00000000000000000000000000000
0.150.310.536.010.560.330.17-1.2-5.32-5.13-0.12-1.7-1.57-2.6140.38-8.76-3.19-2.16-6.085.21-2.06-1.41-3.21-0.12-4.780.2916.35-6.15.45
164-872-146-4900-875639-1,059353-1,462-1,732119-810-942-1400000000000-18,99100
-0.88-2.13-0.813.99-0.9-2.54-0.82-3.94-6.75-7.86-2.78-3.72-5.27-9.44-14.77-18.43-10.72-9.69-14.67-3.96-10.51-10.07-11.12-10.69-14.17-9.67-13.11-16.28-4.24
-1,197-1,561-1,186-1,528-1,451-1,997-651-585-521215858125141-1,837-50,741-4,407-1,790-1,644-2,229-2,457-1,498-1,617-766-3,316-1,716-1,992-2,333-2,340-1,759
000000-981-1,101-1,255-1,482-1,789-2,257-3,027-4,051-4,395-5,265-5,742-5,888-6,362-6,718-6,954-7,040-7,140-7,253-7,682-7,964-8,132-7,832-7,926
1.370.22-0.45-0.330.070.510.570.291.85-2.671.62-1.020.551.16-2.47-0.62.010.68-0.53-0.26-0.010.430.561.96-0.61-0.351.12-1.860.39
9741,1651,3821,336-6861,5142,948-1,1574,7604,8006,3076,1757,2638,62013,82711,33210,74912,59912,91812,59611,1419,85613,81113,23317,48910,70816,32413,0065,226
00000000000000000000000000000

Roche Holding stock margins

The Roche Holding margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Roche Holding. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Roche Holding.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Roche Holding's sales revenue. A higher gross margin percentage indicates that the Roche Holding retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Roche Holding's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Roche Holding's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Roche Holding's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Roche Holding. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Roche Holding's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Roche Holding Margin History

Roche Holding Gross marginRoche Holding Profit marginRoche Holding EBIT marginRoche Holding Profit margin
2029e73.39 %0 %22.12 %
2028e73.39 %35.04 %22.07 %
2027e73.39 %34.87 %22.09 %
2026e73.39 %33.7 %21.73 %
2025e73.39 %33.1 %21.15 %
2024e73.39 %32.26 %20.42 %
202373.39 %31.56 %19.58 %
202270.56 %31.47 %19.63 %
202169.19 %29.51 %22.18 %
202072.74 %32.52 %24.51 %
201971.73 %32.9 %21.96 %
201871.07 %32.92 %18.47 %
201770.54 %31.74 %16.2 %
201670.69 %33.47 %18.93 %
201570.77 %33.36 %18.41 %
201472.79 %35.78 %19.66 %
201373.63 %37.17 %23.86 %
201273.78 %36.62 %20.72 %
201172.58 %34.36 %21.97 %
201072 %28.41 %18.25 %
200970.2 %25.03 %15.87 %
200870.05 %30.46 %19.66 %
200770.21 %31.36 %21.16 %
200668.4 %27.9 %18.74 %
200573.9 %24.72 %16.68 %
200473.86 %20.98 %22.38 %

Roche Holding Stock Sales Revenue, EBIT, Earnings per Share

The Roche Holding earnings per share therefore indicates how much revenue Roche Holding has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Roche Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Roche Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Roche Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Roche Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Roche Holding Revenue, EBIT and net profit per share

DateRoche Holding Sales per ShareRoche Holding EBIT per shareRoche Holding Earnings per Share
2029e114.63 CHF0 CHF25.36 CHF
2028e105.43 CHF0 CHF23.27 CHF
2027e100.35 CHF0 CHF22.17 CHF
2026e98.27 CHF0 CHF21.36 CHF
2025e94.13 CHF0 CHF19.91 CHF
2024e88.97 CHF0 CHF18.16 CHF
202373.03 CHF23.05 CHF14.3 CHF
202278.32 CHF24.65 CHF15.37 CHF
202173.02 CHF21.55 CHF16.2 CHF
202067.43 CHF21.93 CHF16.53 CHF
201971.14 CHF23.41 CHF15.62 CHF
201866.1 CHF21.76 CHF12.21 CHF
201761.98 CHF19.67 CHF10.04 CHF
201658.81 CHF19.68 CHF11.13 CHF
201555.85 CHF18.63 CHF10.28 CHF
201455 CHF19.68 CHF10.81 CHF
201354.21 CHF20.15 CHF12.94 CHF
201253.22 CHF19.49 CHF11.03 CHF
201149.98 CHF17.17 CHF10.98 CHF
201055.39 CHF15.74 CHF10.11 CHF
200957.1 CHF14.29 CHF9.06 CHF
200852.98 CHF16.14 CHF10.42 CHF
200753.52 CHF16.78 CHF11.32 CHF
200648.77 CHF13.61 CHF9.14 CHF
200541.29 CHF10.21 CHF6.89 CHF
200434.77 CHF7.3 CHF7.78 CHF

Roche Holding business model

Roche Holding AG is a Swiss company that operates in the pharmaceutical and diagnostics sectors. It was founded in Basel in 1896 by Fritz Hoffmann-La Roche and is now one of the largest pharmaceutical companies in the world. The business model of Roche is based on research, development, and distribution of innovative medications and diagnostics for the early detection, diagnosis, and treatment of diseases. Its customers include doctors, hospitals, and laboratories. Roche has three operating divisions: Pharma, Diagnostics, and Genentech. The Pharma division is responsible for the development and marketing of prescription drugs, the Diagnostics division offers a wide range of products for disease diagnosis, and the Genentech division focuses on the development of biotechnological drugs. Roche is known for its strong research investments in new medications and has played a significant role in the history of drug development. The company employs approximately 94,000 people worldwide and is listed on the Swiss stock exchange (SIX: ROG). Some of its well-known products include the cancer drug Avastin, the multiple sclerosis drug Ocrevus, and the diabetes medication RoActemra. Roche is also known for its innovative diagnostic products and has developed numerous tests for disease detection. In recent years, the company has expanded its activities into new therapy areas such as immunotherapy and gene therapy, and it has a strong pipeline of new medications and diagnostics that will be launched in the coming years. Overall, Roche has played a significant role in drug development and diagnostics since its inception, and with its research investments and diverse product portfolio, it will continue to play an important role in the healthcare industry. Roche Holding is one of the most popular companies on Eulerpool.com.

Roche Holding SWOT Analysis

Strengths

Roche Holding AG has several strengths that contribute to its success:

  • Strong brand reputation and recognition in the pharmaceutical industry.
  • Diverse portfolio of innovative and life-saving drugs.
  • Extensive research and development capabilities.
  • Global presence with a wide network of subsidiaries and partnerships.
  • Highly skilled and experienced workforce.
  • Strong financial performance with consistent revenue growth.

Weaknesses

While Roche has many strengths, it also faces certain weaknesses:

  • Dependence on a few key drugs for a significant portion of its revenue.
  • High costs associated with drug development and clinical trials.
  • Regulatory hurdles and the risk of litigation in the pharmaceutical industry.
  • Relatively low diversification outside the pharmaceutical sector.
  • Vulnerable to fluctuations in exchange rates and economic conditions.

Opportunities

Roche Holding AG can capitalize on the following opportunities:

  • Increasing global demand for personalized medicine and targeted therapies.
  • Expanding into emerging markets with growing healthcare needs.
  • Investing in digital health and innovative technologies.
  • Acquiring or partnering with smaller biotech companies for portfolio expansion.
  • Collaborating with research institutions and academia for breakthrough discoveries.

Threats

Roche Holding AG should be cautious of the following threats:

  • Intense competition from other pharmaceutical giants.
  • Loss of patent protection and entry of generic competitors.
  • Increasing regulatory scrutiny and pricing pressures.
  • Political and legal uncertainties affecting international operations.
  • Rapidly evolving technological landscape disrupting traditional business models.

Roche Holding historical P/E ratio, EBIT, and P/S ratio.

Roche Holding shares outstanding

The number of shares was Roche Holding in 2023 — This indicates how many shares 804 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Roche Holding earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Roche Holding's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Roche Holding’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Roche Holding's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Roche Holding dividend history and estimates

In 2023, Roche Holding paid a dividend amounting to 9.5 CHF. Dividend means that Roche Holding distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Roche Holding provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Roche Holding’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Roche Holding's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Roche Holding Dividend History

DateRoche Holding Dividend
2029e11.27 CHF
2028e11.27 CHF
2027e11.27 CHF
2026e11.28 CHF
2025e11.25 CHF
2024e11.27 CHF
20239.5 CHF
20229.3 CHF
20219.1 CHF
20209 CHF
20198.7 CHF
20188.3 CHF
20178.2 CHF
20168.1 CHF
20158 CHF
20147.8 CHF
20137.35 CHF
20126.8 CHF
20116.6 CHF
20106 CHF
20095 CHF
20084.6 CHF
20073.4 CHF
20062.5 CHF
20052 CHF
20041.65 CHF

Roche Holding dividend payout ratio

In 2023, Roche Holding had a payout ratio of 57.05%. The payout ratio indicates the percentage of the company's profits that Roche Holding distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Roche Holding represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Roche Holding could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Roche Holding's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Roche Holding Payout Ratio History

DateRoche Holding Payout ratio
2029e58.01 %
2028e58.13 %
2027e58.07 %
2026e57.82 %
2025e58.49 %
2024e57.91 %
202357.05 %
202260.51 %
202156.17 %
202054.48 %
201955.7 %
201868.03 %
201781.75 %
201672.78 %
201577.82 %
201472.16 %
201356.8 %
201261.65 %
201160.11 %
201059.35 %
200955.19 %
200844.19 %
200730.04 %
200627.35 %
200528.99 %
200421.21 %
Unfortunately, there are currently no price targets and forecasts available for Roche Holding.

Roche Holding latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20238.49 CHF8.47 CHF (-0.19 %)2023 Q4
6/30/202310.36 CHF10.1 CHF (-2.52 %)2023 Q2
12/31/20228.9 CHF8.54 CHF (-4 %)2022 Q4
6/30/202211.12 CHF11.76 CHF (5.74 %)2022 Q2
12/31/20219.81 CHF9.25 CHF (-5.73 %)2021 Q4
6/30/202110.41 CHF10.56 CHF (1.41 %)2021 Q2
12/31/20208.93 CHF8.72 CHF (-2.35 %)2020 Q4
6/30/202010.73 CHF10.44 CHF (-2.69 %)2020 Q2
12/31/20199.07 CHF9.04 CHF (-0.38 %)2019 Q4
6/30/201910.79 CHF11.12 CHF (3.11 %)2019 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Roche Holding stock

Eulerpool World ESG Rating (EESG©)

96/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

90

Environment

Scope 1 - Direct Emissions
249,961
Scope 2 - Indirect emissions from purchased energy
114,519
Scope 3 - Indirect emissions within the value chain
4,550,518
Total CO₂ emissions
364,480
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
❌
Pesticides
❌
Palm Oil
❌
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
✅
Hazardous substances
✅
Fuel consumption and efficiency
✅
Water consumption and efficiency
✅

Social

Percentage of female employees51.1
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Roche Holding list of shareholders

%
Name
Stocks
Change
Date
3.37 % The Vanguard Group, Inc.23,252,546198,4073/31/2024
2.90 % Norges Bank Investment Management (NBIM)19,993,397-51,86812/31/2023
1.93 % UBS Asset Management (Switzerland)13,295,573434,1423/31/2024
1.88 % BlackRock Institutional Trust Company, N.A.12,989,728-52,0283/31/2024
1.49 % MFS Investment Management10,316,903-32,5443/31/2024
1.31 % Zürcher Kantonalbank (Asset Management)9,061,7005,1933/31/2024
1.10 % Credit Suisse Asset Management (Schweiz) AG7,606,80839,8523/31/2024
1.08 % BlackRock Advisors (UK) Limited7,423,834200,4373/31/2024
0.90 % Fidelity International6,225,796-136,0992/29/2024
0.73 % Geode Capital Management, L.L.C.5,065,7418803/31/2024
1
2
3
4
5
...
10

Roche Holding Executives and Management Board

Dr. Thomas Schinecker49
Roche Holding Chief Executive Officer, Member of the Corporate Executive Committee
Compensation 9.61 M CHF
Dr. Alan Hippe57
Roche Holding Member of the Corporate Executive Committee, Chief Financial and Information Officer
Compensation 6.05 M CHF
Ms. Cristina Wilbur57
Roche Holding Member of the Corporate Executive Committee, Chief People Officer
Compensation 4.71 M CHF
Ms. Teresa Graham51
Roche Holding Member of the Corporate Executive Committee, Chief Executive Officer of Roche Pharmaceuticals
Compensation 4.68 M CHF
Dr. Severin Schwan57
Roche Holding Non-Executive Chairman of the Board (since 2006)
Compensation 4.54 M CHF
1
2
3
4
...
5

Most common questions regarding Roche Holding

What values and corporate philosophy does Roche Holding represent?

Roche Holding AG represents a strong commitment to innovation, integrity, and patient-centered healthcare. As one of the leading pharmaceutical and diagnostics companies globally, Roche focuses on developing groundbreaking therapeutic solutions and advanced diagnostic tools. The company's core values include scientific excellence, teamwork, and a passion for improving patients' lives. With a dedication to personalized healthcare and a long-standing tradition of ethical conduct, Roche strives to make a positive impact on society. Through continuous research and development efforts, Roche aims to provide effective treatments and diagnostic solutions for various diseases, ultimately contributing to the advancement of healthcare worldwide.

In which countries and regions is Roche Holding primarily present?

Roche Holding AG is primarily present in multiple countries and regions worldwide. The company has a significant presence in Switzerland, where it is headquartered. In addition, Roche Holding AG has a strong presence in the United States, Germany, Japan, China, and other key markets around the globe. With its global reach, Roche Holding AG has established itself as a leading biotechnology and pharmaceutical firm, delivering innovative healthcare solutions to diverse populations across various countries and regions.

What significant milestones has the company Roche Holding achieved?

Roche Holding AG has achieved numerous significant milestones throughout its history. Established in 1896, it has become a leader in the pharmaceutical and diagnostics industry. Some notable milestones include the development of groundbreaking drugs such as Valium, Tamiflu, and Herceptin, which have revolutionized the treatment of various diseases. Roche Holding AG has also been at the forefront of advancing precision medicine with its innovative therapies, such as Avastin and Rituxan. The company's commitment to research and development has resulted in a diverse product portfolio, contributing to its global success and recognition as a leading healthcare company.

What is the history and background of the company Roche Holding?

Roche Holding AG, a renowned global healthcare company, has a rich history and background. Established in 1896 in Switzerland, Roche has become a leader in pharmaceuticals and diagnostics. With major breakthroughs in various therapeutic areas, Roche has contributed significantly to enhancing patient care and improving outcomes. The company's commitment to innovation and research has led to the development of groundbreaking medicines and diagnostic tests, addressing medical needs worldwide. Roche's diverse portfolio includes a range of medicines for oncology, immunology, neuroscience, infectious diseases, and more. With a strong focus on personalized healthcare, Roche continues to shape the future of medicine and positively impact patients' lives globally.

Who are the main competitors of Roche Holding in the market?

The main competitors of Roche Holding AG in the market include Novartis AG, Johnson & Johnson, and Pfizer Inc.

In which industries is Roche Holding primarily active?

Roche Holding AG is primarily active in the pharmaceutical and healthcare industries.

What is the business model of Roche Holding?

The business model of Roche Holding AG is focused on pharmaceuticals and diagnostics. Roche is a global healthcare company that aims to improve people's lives by providing innovative medical solutions. With its innovative research and development capabilities, Roche develops and sells a wide range of pharmaceutical and biotechnology products. The company's diagnostics division specializes in developing and manufacturing diagnostic tests and systems to support personalized healthcare. Through ongoing investments in research, Roche strives to address unmet medical needs and improve patient outcomes. As a leading player in the healthcare industry, Roche is committed to delivering high-quality and effective healthcare solutions to individuals worldwide.

What is the P/E ratio of Roche Holding 2024?

The Roche Holding P/E ratio is 17.79.

What is the P/S ratio of Roche Holding 2024?

The Roche Holding P/S ratio is 3.63.

What is the AlleAktien quality score of Roche Holding?

The AlleAktien quality score for Roche Holding is 6/10.

What is the revenue of Roche Holding 2024?

The expected Roche Holding revenue is 61.44 B CHF.

How high is the profit of Roche Holding 2024?

The expected Roche Holding profit is 12.54 B CHF.

What is the business model of Roche Holding

The Roche Holding AG is a Swiss pharmaceutical company based in Basel. The company operates worldwide and specializes in the development and production of medications, as well as diagnostic and laboratory equipment. Roche is divided into two core business areas: pharmaceuticals and diagnostics. In the pharmaceuticals area, Roche specializes in the development of medications and therapies in the fields of oncology, immunology, virology, metabolic disorders, and CNS diseases. Some of Roche's most well-known medications include Avastin, Herceptin, MabThera, and Rituxan. These medications are used for the treatment of cancer and other serious diseases. In the diagnostics area, Roche holds a leading position in the field of in-vitro diagnostics (IVD) and offers tests and test systems for a variety of diseases. Roche is the world's largest provider of IVD tests and offers tests for the diagnosis of cancer, infectious diseases, blood clots, and cardiovascular diseases, among others. The company has also developed instruments and software to improve laboratory efficiency and accuracy. Roche has extensive expertise in medicine and the life sciences, and the company is committed to developing innovative therapies and solutions that improve healthcare. Roche's focus on research and development is evident - the company invests more than 11 billion Swiss francs annually in research and development projects and collaborates with leading research institutions. Roche's business model is focused on creating value for patients, customers, employees, and investors. The company places great importance on innovation, patient orientation, and sustainability, and is committed to protecting the environment and reducing CO2 emissions. Roche also pursues a targeted acquisition strategy to strengthen its presence in selected markets and acquire new technologies. In 2018, Roche acquired the US company Foundation Medicine, a leading company in the field of personalized oncology and diagnostics. With this acquisition, Roche strengthened its presence in the field of personalized medicine. Overall, Roche's business model is focused on long-term growth by developing innovative medications and diagnostic tests to meet the unmet need for healthcare services. The company is committed to improving healthcare worldwide and strives to ensure that patients can be treated faster and more effectively, and that diseases can be identified as early as possible.

What is the Roche Holding dividend?

Roche Holding pays a dividend of 9.3 CHF distributed over 1 payouts per year.

How often does Roche Holding pay dividends?

Roche Holding pays out a dividend 1 times a year.

What is the Roche Holding ISIN?

The ISIN of Roche Holding is CH0012032048.

What is the Roche Holding WKN?

The WKN of Roche Holding is 855167.

What is the Roche Holding ticker?

The ticker of Roche Holding is ROG.SW.

How much dividend does Roche Holding pay?

Over the past 12 months, Roche Holding paid a dividend of 9.5 CHF . This corresponds to a dividend yield of about 3.42 %. For the coming 12 months, Roche Holding is expected to pay a dividend of 11.25 CHF.

What is the dividend yield of Roche Holding?

The current dividend yield of Roche Holding is 3.42 %.

When does Roche Holding pay dividends?

Roche Holding pays a quarterly dividend. This is distributed in the months of April, April, April, April.

How secure is the dividend of Roche Holding?

Roche Holding paid dividends every year for the past 37 years.

What is the dividend of Roche Holding?

For the upcoming 12 months, dividends amounting to 11.25 CHF are expected. This corresponds to a dividend yield of 4.05 %.

In which sector is Roche Holding located?

Roche Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Roche Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Roche Holding from 3/18/2024 amounting to 9.6 CHF, you needed to have the stock in your portfolio before the ex-date on 3/14/2024.

When did Roche Holding pay the last dividend?

The last dividend was paid out on 3/18/2024.

What was the dividend of Roche Holding in the year 2023?

In the year 2023, Roche Holding distributed 9.3 CHF as dividends.

In which currency does Roche Holding pay out the dividend?

The dividends of Roche Holding are distributed in CHF.

All fundamentals about Roche Holding

Our stock analysis for Roche Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Roche Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.